Nagahiro Saijo

Summary

Publications

  1. pmc The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncology
    Nagahiro Saijo
    Japanese Society of Medical Oncology, Tokyo, Japan
    Yonsei Med J 54:1-14. 2013
  2. doi request reprint Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms
    Emiko Sugiyama
    Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan
    Clin Pharmacokinet 49:549-58. 2010
  3. ncbi request reprint Genetic variations of VDR/NR1I1 encoding vitamin D receptor in a Japanese population
    Maho Ukaji
    Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan
    Drug Metab Pharmacokinet 22:462-7. 2007
  4. ncbi request reprint CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population
    Yoshiro Saito
    Division of Biochemistry and Immunochemistry, National Institute of Health Sciences, Tokyo, Japan
    Pharmacogenet Genomics 17:461-71. 2007
  5. ncbi request reprint Fourteen novel genetic variations and haplotype structures of the TYMS gene encoding human thymidylate synthase (TS)
    Su Ryang Kim
    Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan
    Drug Metab Pharmacokinet 21:509-16. 2006
  6. ncbi request reprint Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than *15
    Su Ryang Kim
    Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan
    Drug Metab Pharmacokinet 22:456-61. 2007
  7. ncbi request reprint Haplotypes and a novel defective allele of CES2 found in a Japanese population
    Su Ryang Kim
    Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan
    Drug Metab Dispos 35:1865-72. 2007
  8. ncbi request reprint Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism
    Emiko Sugiyama
    Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan
    J Clin Oncol 25:32-42. 2007
  9. ncbi request reprint Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer
    Ikuo Sekine
    Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
    J Thorac Oncol 1:810-5. 2006
  10. ncbi request reprint Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences
    Keiko Maekawa
    Division of Biochemistry and Immunochemistry, National Institute of Health Sciences, 1 18 1 Kamiyoga, Setagaya Ku, Tokyo, 158 8501, Japan
    J Hum Genet 52:804-19. 2007

Collaborators

Detail Information

Publications54

  1. pmc The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncology
    Nagahiro Saijo
    Japanese Society of Medical Oncology, Tokyo, Japan
    Yonsei Med J 54:1-14. 2013
    ....
  2. doi request reprint Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms
    Emiko Sugiyama
    Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan
    Clin Pharmacokinet 49:549-58. 2010
    ..The aim of this study was to determine the factors, including genetic polymorphisms of CDA, DCK and solute carrier family 29A1 (SLC29A1 [hENT1]), that alter the pharmacokinetics of gemcitabine in Japanese cancer patients...
  3. ncbi request reprint Genetic variations of VDR/NR1I1 encoding vitamin D receptor in a Japanese population
    Maho Ukaji
    Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan
    Drug Metab Pharmacokinet 22:462-7. 2007
    ..430, 0.636, and 0.318 allele frequencies, respectively. Another SNP, -26930A>G, with reduced VDR transcription was found at a 0.028 frequency. These findings would be useful for association studies on VDR variations in Japanese...
  4. ncbi request reprint CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population
    Yoshiro Saito
    Division of Biochemistry and Immunochemistry, National Institute of Health Sciences, Tokyo, Japan
    Pharmacogenet Genomics 17:461-71. 2007
    ..Although large interindividual differences in CYP2C8 enzymatic activity and several nonsynonymous variations were reported, neither haplotype structures nor their associations with pharmacokinetic parameters of paclitaxel were reported...
  5. ncbi request reprint Fourteen novel genetic variations and haplotype structures of the TYMS gene encoding human thymidylate synthase (TS)
    Su Ryang Kim
    Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan
    Drug Metab Pharmacokinet 21:509-16. 2006
    ..In Blocks 1 and 3, 7 and 19 haplotypes were determined/inferred, respectively. Our findings provide fundamental and useful information for genotyping TYMS in the Japanese and probably other Asian populations...
  6. ncbi request reprint Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than *15
    Su Ryang Kim
    Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan
    Drug Metab Pharmacokinet 22:456-61. 2007
    ..469, 0.000 (not detected), 0.037, and 0.133, respectively. These data would provide fundamental and useful information for pharmacogenetic studies on OATP1B1-transported drugs in Japanese...
  7. ncbi request reprint Haplotypes and a novel defective allele of CES2 found in a Japanese population
    Su Ryang Kim
    Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan
    Drug Metab Dispos 35:1865-72. 2007
    ..These findings are useful for further pharmacogenetic studies on CES2-activated prodrugs...
  8. ncbi request reprint Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism
    Emiko Sugiyama
    Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan
    J Clin Oncol 25:32-42. 2007
    ..This study extended the investigation of the effects of CDA genetic polymorphisms on gemcitabine pharmacokinetics and toxicities...
  9. ncbi request reprint Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer
    Ikuo Sekine
    Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
    J Thorac Oncol 1:810-5. 2006
    ..To evaluate the feasibility and efficacy of docetaxel consolidation therapy after concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer (NSCLC)...
  10. ncbi request reprint Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences
    Keiko Maekawa
    Division of Biochemistry and Immunochemistry, National Institute of Health Sciences, 1 18 1 Kamiyoga, Setagaya Ku, Tokyo, 158 8501, Japan
    J Hum Genet 52:804-19. 2007
    ..This study provides fundamental information for pharmacogenetic studies for evaluating the efficacy and toxicity of 5-FU in Japanese and probably East Asians...
  11. ncbi request reprint Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients
    Kimie Sai
    Division of Biosignaling, National Institute of Health Sciences, 1 18 1 Kamiyoga, Setagaya Ku, Tokyo, Japan
    Cancer Chemother Pharmacol 62:529-37. 2008
    ..In this study, the effects of CYP3A4 haplotypes including *16B on irinotecan PK/PD were investigated in irinotecan-administered patients...
  12. doi request reprint Genetic variation and haplotype structures of the glutathione S-transferase genes GSTA1 and GSTA2 in Japanese colorectal cancer patients
    Keiko Maekawa
    Division of Medicinal Safety Science, National Institute of Health Sciences, Tokyo, Japan
    Drug Metab Pharmacokinet 26:646-58. 2011
    ..Finally, haplotype combinations of both genes were classified into 3 major types: GSTA1*A-GSTA2*C, GSTA1*A-GSTA2*B, and GSTA1*B-GSTA2*E. These findings will be useful in pharmacogenomic studies on xenobiotics including anticancer drugs...
  13. ncbi request reprint Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer
    Hirokazu Watanabe
    Division of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 33:626-30. 2003
    ..We conducted a dose-finding and feasibility study in which we administered a fixed dose 3-h infusion of paclitaxel and an escalating dose of cisplatin in Japanese patients with advanced non-small cell lung cancer...
  14. ncbi request reprint Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK)
    Su Ryang Kim
    Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan
    Drug Metab Pharmacokinet 23:379-84. 2008
    ..Our findings suggest considerable ethnic differences in genetic variations of DCK and provide fundamental and useful information for genotyping DCK in the Japanese and probably other Asian populations...
  15. ncbi request reprint Genetic variations and haplotype structures of the glutathione S-transferase genes, GSTT1 and GSTM1, in a Japanese patient population
    Naoko Tatewaki
    National Institute of Health Sciences, Tokyo, Japan
    Drug Metab Pharmacokinet 24:118-26. 2009
    ..Three and six common haplotypes (N> or =10) in GSTT1 and GSTM1, respectively, accounted for most (>95%) inferred haplotypes. This information would be useful in pharmacogenomic studies of xenobiotics including anticancer drugs...
  16. ncbi request reprint Genetic polymorphisms and haplotypes of por, encoding cytochrome p450 oxidoreductase, in a Japanese population
    Yoshiro Saito
    Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan
    Drug Metab Pharmacokinet 26:107-16. 2011
    ..03 frequencies accounted for more than 81% of the inferred haplotypes. This study provides fundamental and useful information for the pharmacogenetic studies of drugs metabolized by CYPs in the Japanese population...
  17. ncbi request reprint Genetic polymorphisms of UGT1A6 in a Japanese population
    Mayumi Saeki
    Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan
    Drug Metab Pharmacokinet 20:85-90. 2005
    ..Our results provide fundamental and useful information for genotyping UGT1A6 in the Japanese, and probably Asian populations...
  18. ncbi request reprint Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin
    Kan Yonemori
    Division of Hepatobiliary and Pancreatic Oncology and Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Clin Cancer Res 11:2620-4. 2005
    ....
  19. ncbi request reprint Genetic variation and haplotype structure of the ABC transporter gene ABCG2 in a Japanese population
    Keiko Maekawa
    Project Team for Pharmacogenetics, Division of Biochemistry and Immunochemistry, National Institute of Health Sciences, Kamiyoga, Tokyo, Japan
    Drug Metab Pharmacokinet 21:109-21. 2006
    ..This study provides fundamental information for the pharmacogenetic studies investigating the relationship between the genetic variations in ABCG2 and pharmacokinetic/pharmacodynamic parameters...
  20. ncbi request reprint Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol
    Noboru Yamamoto
    Division of Internal Medicine, National Cancer Center Hospital, 5 1 1, Tsukiji, Chuo Ku, Tokyo, 104 0045, Japan
    J Clin Oncol 23:1061-9. 2005
    ..This study was designed to assess whether the application of our method to individualized dosing could decrease pharmacokinetic (PK) and pharmacodynamic (PD) variability compared with body-surface area (BSA) -based dosing...
  21. doi request reprint Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel
    Yasunori Sato
    Genetics Division, National Cancer Center Research Institute, Tokyo, Japan
    J Thorac Oncol 6:132-8. 2011
    ..Our goal was to identify candidate polymorphisms that could influence overall survival (OS) in advanced non-small cell lung cancer (NSCLC) patients treated with carboplatin (CBDCA) and paclitaxel (PTX)...
  22. ncbi request reprint Topoisomerase I inhibitors in small-cell lung cancer. The Japanese experience
    Nagahiro Saijo
    Division of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan
    Oncology (Williston Park) 18:11-6. 2004
    ..In arm B, the response rate was 77% and the median overall survival was 12.9 months. A randomized trial comparing IP with IPE administered every 3 weeks in patients with previously untreated ED-SCLC is presently being performed in Japan...
  23. ncbi request reprint Genetic variations and haplotypes of ABCC2 encoding MRP2 in a Japanese population
    Kimie Sai
    Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan
    Drug Metab Pharmacokinet 23:139-47. 2008
    ..Moreover, the allele 1446C>T (Thr482Thr), which has increased activity, was not detected in our Japanese population. These findings imply possible differences in MRP2-mediated drug responses between Asians and Caucasians...
  24. doi request reprint Genetic polymorphisms of FCGR2A encoding Fcγ receptor IIa in a Japanese population and functional analysis of the L273P variant
    Minoru Tada
    Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, Setagaya Ku, Tokyo, Japan
    Immunogenetics 64:869-77. 2012
    ..The current results suggest that L273P could have functional significance in the antibody-dependent clinical responses through FcγRIIa...
  25. ncbi request reprint A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors
    Tomohide Tamura
    National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    J Thorac Oncol 1:1002-9. 2006
    ..This study assessed the safety and tolerability of escalating doses of ZD6474 in Japanese patients with solid, malignant tumors...
  26. ncbi request reprint Genes regulating the sensitivity of solid tumor cell lines to cytotoxic agents: a literature review
    Ikuo Sekine
    Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 37:329-36. 2007
    ..We conclude that a total of 80 in vitro chemosensitivity associated genes identified in the literature are potential candidates for clinical predictive chemosensitivity testing...
  27. doi request reprint Identification of a predictive biomarker for hematologic toxicities of gemcitabine
    Junichi Matsubara
    Chemotherapy Division, National Cancer Center Research Institute, Tokyo, Japan
    J Clin Oncol 27:2261-8. 2009
    ..This study aimed to discover a new diagnostic method for predicting the hematologic toxicities of gemcitabine...
  28. ncbi request reprint AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor
    Masayuki Takeda
    Shien Lab, National Cancer Center Hospital, Tsukiji, Chuo Ku, Tokyo, Japan
    Clin Cancer Res 13:3051-7. 2007
    ..The purpose of this study was to investigate the activity of AZD2171 in gastric cancer...
  29. ncbi request reprint Phase I trial of weekly docetaxel in elderly patients with non-small cell lung cancer
    Akira Inoue
    Department of Medical Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo, Japan
    Lung Cancer 38:205-9. 2002
    ..Although other hematological and non-hematological toxicities observed in this treatment were generally moderate and were well tolerated by elderly patients with NSCLC, the risk of myelosuppression still requires careful attention...
  30. doi request reprint Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials
    Yasuo Ohashi
    Department of Biostatistics, School of Public Health, University of Tokyo, Tokyo, Japan
    Cancer Sci 104:481-5. 2013
    ..No increase in thromboembolic events was observed in the ESA-treated patients (0.7% vs 1.7% placebo). The ESA reduced the risk of transfusion without a negative impact on the survival of patients with chemotherapy-induced anemia...
  31. ncbi request reprint Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells
    Fumiaki Koizumi
    Support Facility of Project Ward, National Cancer Center Hospital, Tokyo, Japan
    Int J Cancer 108:464-72. 2004
    ....
  32. ncbi request reprint Retrospective analysis of safety and efficacy of low-dose docetaxel 60 mg/m2 in advanced non-small cell lung cancer patients previously treated with platinum-based chemotherapy
    Yoichi Nakamura
    Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Am J Clin Oncol 26:459-64. 2003
    ..Further investigation of the optimal docetaxel dose as second-line chemotherapy in NSCLC is warranted...
  33. ncbi request reprint Establishment of a human non-small cell lung cancer cell line resistant to gefitinib
    Fumiaki Koizumi
    Shien Lab, National Cancer Center Hospital, Tokyo, Japan
    Int J Cancer 116:36-44. 2005
    ..These phenotypes including EGFR-SOS complex and heterodimer formation of HER family members are potential biomarkers for predicting resistance to gefitinib...
  34. doi request reprint Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma
    Makoto Nishio
    Thoracic Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto ku, Tokyo, Japan
    J Thorac Oncol 6:1889-94. 2011
    ....
  35. ncbi request reprint Retrospective analysis of steroid therapy for radiation-induced lung injury in lung cancer patients
    Ikuo Sekine
    Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
    Radiother Oncol 80:93-7. 2006
    ..To disclose characteristics of lung cancer patients developing radiation-induced lung injury treated with or without corticosteroid therapy...
  36. ncbi request reprint Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib
    Koichi Ando
    First Department of Internal Medicine and Institute of Molecular Oncology, Showa University, and Internal Medicine, Pharmacology Division, National Cancer Center Hospital, Tokyo, Japan
    Clin Cancer Res 11:8872-9. 2005
    ..These results suggest that therapy with TNF-alpha would be effective in some cases of non-small-cell lung cancer that have acquired resistance to gefitinib...
  37. ncbi request reprint Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor
    Kazuko Sakai
    Shien Lab, Medical Oncology, National Cancer Center Research Institute, Tokyo, Japan
    FASEB J 20:311-3. 2006
    ..Gefitinib-inhibited phospho-AKT predominantly in deletional EGFR expressing cells...
  38. ncbi request reprint Genetic polymorphisms of FCGRT encoding FcRn in a Japanese population and their functional analysis
    Akiko Ishii-Watabe
    Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, Tokyo, Japan
    Drug Metab Pharmacokinet 25:578-87. 2010
    ..These results suggested that at least no common functional polymorphic site with amino acid change was present in the FCGRT of our Japanese population...
  39. ncbi request reprint Novel genetic polymorphisms in the NR3C1 (glucocorticoid receptor) gene in a Japanese population
    Satoru Koyano
    Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan
    Drug Metab Pharmacokinet 20:79-84. 2005
    ..Thus, ethnic differences between Japanese and other races are suggested to exist in NR3C1...
  40. ncbi request reprint hnRNP L enhances sensitivity of the cells to KW-2189
    Fumiko Taguchi
    Pharmacology Division, National Cancer Center Research Institute, Tokyo, Japan
    Int J Cancer 108:679-85. 2004
    ..hnRNP L is a factor that determines the sensitivities of cancer cells to the minor groove binder, and overexpression and differential intracellular localization of hnRNP L are involved in its function in lung cancer...
  41. doi request reprint A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer
    Ikuo Sekine
    Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5 1 1, Chuo Ku, Tokyo, 104 0045, Japan
    Int J Clin Oncol 14:112-9. 2009
    ..We aimed to identify, through a review of the literature, candidate genes for a prospective predictive chemosensitivity test in patients with breast cancer...
  42. ncbi request reprint A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with lung cancer
    Ikuo Sekine
    Divisions of Thoracic Oncology and Internal Medicine, National Cancer Center Hospital, Tokyo, Japan
    J Thorac Oncol 1:31-7. 2006
    ..To find candidate genes for a predictive chemosensitivity test in patients with lung cancer by using a literature review...
  43. doi request reprint Developments for a growing Japanese patient population: facilitating new technologies for future health care
    Harubumi Kato
    Dept of Surgery, Tokyo Medical University, Tokyo, Japan
    J Proteomics 74:759-64. 2011
    ....
  44. ncbi request reprint Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population
    Hiroyuki Hichiya
    Project Team for Pharmacogenetics, National Institute of Health Sciences, Setagaya Ku, Tokyo, Japan
    Drug Metab Dispos 33:630-6. 2005
    ..These results indicate that the novel CYP2C8 SNPs, 556C>T (R186X) and 556C>G (R186G), could influence the metabolism of CYP2C8 substrates such as paclitaxel and cerivastatin...
  45. ncbi request reprint Phase I/II study of 3-week cycle cisplatin-gemcitabine in advanced non-small cell lung cancer
    Hitoshi Kusaba
    Division of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 32:43-7. 2002
    ..This study was performed to determine the maximum tolerated dose of gemcitabine combined with cisplatin in a 3-week cycle regimen and to observe safety and efficacy for Japanese patients with advanced non-small cell lung cancer...
  46. ncbi request reprint Genetic variations of the AHR gene encoding aryl hydrocarbon receptor in a Japanese population
    Hiromi Fukushima-Uesaka
    Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan
    Drug Metab Pharmacokinet 19:320-6. 2004
    ..The allele frequencies were 0.010 for 1459A>G (Asn487Asp) and 0.002 for the other 3 variations. Also detected in this analysis was the known nonsynonymous single nucleotide polymorphism 1661G>A (Arg554Lys) at a 0.444 frequency...
  47. ncbi request reprint Strategy for the development of novel anticancer drugs
    Nagahiro Saijo
    National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, 104 0045, Tokyo, Japan
    Cancer Chemother Pharmacol 52:S97-101. 2003
    ..The problems and future prospects of novel anticancer drug development are discussed...
  48. ncbi request reprint Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebo-controlled study
    Masahiro Tsuboi
    Department of Thoracic Surgery and Oncology, Tokyo Medical University and Hospital, 6 7 1 Nishi shinjuku, Shinjuku ku, Tokyo, Japan
    Jpn J Clin Oncol 39:163-8. 2009
    ..The efficacy and safety of weekly administration of epoetin beta (EPO) for chemotherapy-induced anemia (CIA) patients was evaluated...
  49. ncbi request reprint Translational studies for target-based drugs
    Kazuto Nishio
    Shien Lab, National Cancer Center Hospital, Tsukiji 5 1 1, Chuo Ku, 104 0045, Tokyo, Japan
    Cancer Chemother Pharmacol 56:90-3. 2005
    ..Novel approaches for the detection of EGFR mutation in other clinical samples such as cytology, pleural effusion and circulating tumor cells are ongoing...
  50. ncbi request reprint [Developed new agents for lung cancer]
    Yasufumi Kato
    Department of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan
    Nihon Geka Gakkai Zasshi 103:218-23. 2002
    ..The development of new agents, particularly molecular target-based drugs and multimodality treatment, is necessary to improve the therapeutic results in lung cancer further...
  51. ncbi request reprint Mechanism of vinorelbine-induced radiosensitization of human small cell lung cancer cells
    Kazuya Fukuoka
    Pharmacology Division, National Cancer Center Research Institute, Tokyo, Japan
    Cancer Chemother Pharmacol 49:385-90. 2002
    ....
  52. ncbi request reprint Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509
    Miyako Satouchi
    Miyako Satouchi, Hyogo Cancer Center, Akashi Yoshikazu Kotani, Kobe University Graduate School of Medicine, Kobe Taro Shibata and Haruhiko Fukuda, Japan Clinical Oncology Group Data Center, Multi institutional Clinical Trial Support Center, National Cancer Center Yuichiro Ohe, National Cancer Center Hospital East Makoto Nishio, Cancer Institute Hospital, Japanese Foundation For Cancer Research Tomohide Tamura, National Cancer Center Hospital Nagahiro Saijo, Japanese Society of Medical Oncology, Tokyo Masahiko Ando, Kyoto University School of Public Health, Kyoto Kazuhiko Nakagawa, Kinki University School of Medicine Koji Takeda, Osaka City General Hospital Tatsuo Kimura, Graduate School of Medicine, Osaka City University Shinji Atagi, National Hospital Organization Kinki chuo Chest Medical Center, Osaka Nobuyuki Yamamoto, Shizuoka Cancer Center, Shizuoka Yukito Ichinose, National Hospital Organization Kyushu Cancer Center, Fukuoka Toyoaki Hida, Aichi Cancer Center, Nagoya Koichi Minato, Gunma Cancer Center, Gunma and Akira Yokoyama, Niigata Cancer Center Hospital, Niigata, Japan
    J Clin Oncol 32:1262-8. 2014
    ....
  53. ncbi request reprint Phase II study of twice-daily high-dose thoracic radiotherapy alternating with cisplatin and vindesine for unresectable stage III non-small-cell lung cancer: Japan Clinical Oncology Group Study 9306
    Ikuo Sekine
    Department of Internal Medicine, National Cancer Center Hospital, Tokyo, Japan
    J Clin Oncol 20:797-803. 2002
    ..To evaluate the efficacy and toxicity of high-dose thoracic radiotherapy (TRT) alternating with chemotherapy (CH) for unresectable stage III non--small-cell lung cancer (NSCLC)...
  54. ncbi request reprint UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer
    Kimie Sai
    Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan
    Clin Pharmacol Ther 75:501-15. 2004
    ....